Saniona (SANION) Q1 2025 earnings summary

Executive summary

• Revenue increased to SEK 9.8 million in Q1 2025 from SEK 6.0 million year-over-year, driven by expanded licensing and partnership agreements.

• Net profit reached SEK 19.0 million, reversing a loss of SEK 9.2 million in Q1 2024, mainly due to a fair value gain on TO4 warrants.

• Cash and cash equivalents rose to SEK 260.7 million from SEK 71.4 million, supported by successful TO4 warrant exercise and strong financing activities.

• Strategic pipeline progress included re-initiation of all three internal development programs and positive regulatory developments for tesofensine.

• Key management changes: John Haurum proposed as Chairman, Pierandrea Muglia appointed CMO, and Johnny Stilou named CFO post-period.

Financial highlights

• Operating loss widened to SEK -16.4 million from SEK -13.7 million year-over-year, reflecting higher R&D and personnel costs.

• Net financial income surged to SEK 34.0 million, mainly from a SEK 33.7 million fair value gain on TO4 warrants (non-cash effect).

• Basic EPS improved to SEK 0.17 from SEK -0.08; diluted EPS at SEK 0.16.

• Equity ratio strengthened to 68% from 25% year-over-year.

• Cash flow from operations was SEK -31.9 million, reflecting increased operating loss and tax payments.

Outlook and guidance

• All three internal development programs (SAN2355, SAN2219, SAN2465) are advancing toward Phase 1 trials, with Phase 2 expected in 2–3 years.

• Tesofensine regulatory progress in Mexico could unlock near-term royalty revenue and new market opportunities.

• Additional strategic partnerships are actively being pursued to secure non-dilutive financing and expand the pipeline.